Bayer Animal Health has launched Baytril® Max 100mg/ml Solution for Injection for Cattle and Pigs, which replaces the company's previously animal-specific Baytril Max products.
Bayer says the active ingredient, enrofloxacin, treats bacterial infection by inhibiting the action of bacterial DNA gyrase resulting in bacterial cell death.
In cattle, Baytril Max treats respiratory infections and mastitis caused by enrofloxacin-sensitive Histophilus somni, Mannheimia haemolytica, Pasteurella multocida and Mycoplasma spp., and enrofloxacin-sensitive E. coli respectively.
In pigs, Baytril Max targets bacterial bronchopneumonia caused by enrofloxacin-sensitive Actinobacillus pleuropneumoniae, Pasteurella multocida and complicated by Haemophilus parasuis as a secondary pathogen in pigs.
Bayer advises that vets treating cattle for respiratory infections should inject subcutaneously. Mastitis cases should be treated intravenously and pigs should be injected intramuscularly in the neck muscles, behind the ear.
The development of the Baytril Max product family provides vets with greater treatment flexibility from one solution.
For further information please visit www.noahcompendium.co.uk
The company is now inviting practices to sign up for the free Beta trial and shape the development of the new platform and how video consultations can be integrated into traditional ways of working.
The platform, which can be branded with the practice logo, uses an app which clients download onto their mobile devices and use to book appointments. The system has its own appointment booking system, but also integrates with Vetstoria. When an appointment is booked via video, practitioners see it in their PMS. They then visit their online account, select the relevant appointment and click ‘start video call’. Payment can be collected from the owner prior to the consultation.
Susie Samuel, Managing Director of VetHelpDirect said: "While developing this product, we have been mindful that the use of telemedicine in our industry has been hugely controversial. We believe that inviting local vets to trial and refine this technology, using their team to work with their own clients removes many of the risks and dangers otherwise inherent in the proposition."
I agree wholeheartedly. The controversy over telemedicine has been about the idea of allowing the prescription of drugs to animals that have not been seen in person. Using a service like this (or the one launched by the Virtual Vet Group last year) to offer video consultations to patients that are already under your care strikes me as an altogether different kettle of fish. I think it will help improve engagement with existing clients, by reducing unnecessary trips to the practice for follow-up or post-operative consultations, saving time, money and the planet.
Susie added: "In our fast-moving world pet owners are increasingly reliant on technology and expect to be able to access services easily. The results of our recent VetHelpDirect research of 419 owners showed 38% of survey respondents said they would like to have the option of a video consultation if it was offered by their own vet. If we are to keep up with this demand, we need to embrace new ways of working."
VetHelpDirect says that whilst it believes that the growth in the use of this technology will change the way veterinary medicine is practiced, video consultations will always work alongside in-person consultations, as just one tool in an overall strategy of care, and certainly will not replace face to face diagnosis.
Let's hope so.
Susie added: "What is clear from our research is that whilst clients would like to be able to have video consultations with a vet their strong preference is for this to be with their own vet; whilst 38% of people would use video consultations with their own vet this falls to only 7% if it is provided by a vet not known to them.
"Of course, telemedicine is by no means the answer in every case, what the new service does offer is flexibility for practitioners and the ability to work in new ways that will benefit the animals and owners. For example, giving free telephone advice has become common place in many practices but is very hard to monetise. Video consultations provide a commercial solution to this problem.”
For more information, or to join the trial, contact Susie Samuel susie@vethelpdirect.com
The company says its new design is modular, allowing veterinary practices to customise kennels to their requirements now, and then upgrade them and add components as their needs change over time.
Options include dimmable daylight lighting or Casco Pet’s DRC Lighting System with three modes: Daylight (white), Recovery (red), and Cleaning (blue UVA), built-in thermostatically controlled heat mats, an illuminated glass whiteboard for easy recording and viewing of patient notes, integrated IV stand and pump holders, an internal ceiling vent and ventilation kit and an integrated plug socket and USB port .
Matthew Bubear, CEO, Casco Pet, said: “Our new generation of WellKennels, which have been designed to meet the dynamic demands of modern veterinary practices, allow practitioners to elevate the care they provide today while ensuring sustained adaptability for the needs of tomorrow."
WellKennels are certified by the International Society of Feline Medicine and are part of FearFree’s Preferred Product Program, the global initiative dedicated to preventing and alleviating fear, anxiety and stress in pets.
The new WellKennels will be unveiled at the London Vet Show, ExCel London, 16-17 November, on Stand H35.
https://cascopet.com/uk/products-and-services/veterinary
The Kennel Club is calling on the profession to support Get Fit With Fido, its new campaign to help tackle the growing dog obesity crisis by educating owners about the range of different ways to get fit with their dogs..
In addition to the education campaign, Get Fit With Fido also includes a challenge that rewards the dog and dog owner who jointly lose the most weight, and the dog owner and dog who individually lose the most weight, as a result of exercising together. Prizes include a one night stay at the dog friendly, 4* boutique townhouse hotel Flemings Mayfair; a luxury dog bed from Charley Chau and Champagne Afternoon Tea for Two at the Milestone Hotel.
All dog owners who enter Get Fit With Fido, will receive a 20% discount on Crufts and Discover Dogs tickets; as well as advice, tips and tools for owners.
Veterinary practices are being asked to support the campaign by requesting free flyers and posters from the Kennel Club and then displaying them at reception, or in the waiting room.Caroline Kisko, Kennel Club Secretary, said: "Reports indicate that between 30 and 60% of all dogs are overweight so it is more important than ever we keep our dogs happy and healthy. One of the most serious findings in obesity studies that have proven to be related to being overweight in both humans and dogs is a reduced lifespan. An overweight dog is more likely to die younger than a dog of normal weight.
"The findings are shocking and we are trying to educate as many dog owners as possible and call on vets to spread the message of keeping your dog fit and healthy."
To get involved in Get Fit With Fido and receive free flyers and posters, contact the Kennel Club press office at gfwf@thekennelclub.org.uk
For more information, visit www.thekennelclub.org.uk/getfitwithfido
York-based Alstoe Animal Health, maker of Gleptosil and Vetergesic, has been acquired by French company Sogeval, a leading supplier of companion and livestock animal products.
Established in 1994, Alstoe was privatelv owned by the two original partners, John Nellis and lan Ryder.
For the last five years the company has been working with Sogeval to develop flavoured tablet pharmaceutical brands from Sogeval whilst the two companies have collaborated to make Vetergesic successful in France.
The business will continue to trade from the current premises for the foreseeable future and says it will maintain its high standard of customer service and product supply.
John Nellis said: "lt will be business as usual. We look forward to continued sales growth for our existing brands and the introduction of exciting new products in the future".
Dr. lan Ryder said: "Our companies have worked very well together in the past. The acquisition will bring fresh impetus to the business and ensure continued growth"
The current Alstoe team remains in place to assist with any enquiries. For further information contact info@alstoe.co.uk or telephone: 01347 878605
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.
The current strain of bluetongue emerged in the Netherlands in 2023 and spread rapidly, infecting over 5,000 livestock farms.
Infection of livestock with this serotype of the virus can result in severe clinical signs and high mortality rates1, significantly impacting animal health, and farming communities.
Bultavo 3 is an inactivated injectable vaccine indicated for the active immunisation against BTV-3.
Boehringer says that in sheep, Bultavo 3 has been shown to significantly reduce viraemia and prevent mortality and clinical signs associated with BTV-3 infection.
Onset of immunity occurs three weeks after administration of a single 1ml subcutaneous dose in sheep.
In cattle, two 1ml intramuscular doses are required, at a three-week interval.
Findlay MacBean, Head of Livestock, UK and Ireland at Boehringer Ingelheim, said: “It’s great news that we can support farmers and authorities in their fight against bluetongue with our new BTV-3 vaccine, Bultavo 3.
"As we have seen across Europe, and now in the UK, BTV can spread rapidly and causes considerable stress to farmers because of the significant financial impact on those affected.
The availability of Bultavo 3 means future BTV-3 outbreaks can be suppressed, helping farmers protect not only their herds, but also their livelihoods.” Oli Maxwell, BVSc BSc(Hons) MVM DipECBHM, RCVS Recognised Specialist in Cattle Health and Production and Clinical Director of Green Counties Vets said: “Farmers are justifiably concerned about BTV-3 and its incursion into the UK again this year.
"Reports from colleagues on the continent regarding the severity of clinical signs, especially in sheep are worrying.
"We have seen a huge increase in clients asking about the disease, progress on a vaccine and what this may mean for animal movements at a critical time of year.
"The availability of a safe and effective vaccine as a critical tool against a disease that we can’t reasonably prevent with biosecurity measures will be a welcome development for many.”
To manage supply and demand, use of the product will initially be subject to geographical restriction with vaccination permitted in high-risk English counties: Norfolk, Suffolk, Essex, Kent and East Sussex.
Reference:
The Investigating Committee and the Disciplinary Committee are responsible for conducting desk-top investigations and disciplinary hearings in response to complaints, disclosures and notifications that may amount to serious professional misconduct by Registered Farriers.
As the Royal College of Veterinary Surgeons did in 2015, the FRC is splitting off its disciplinary functions from that of its Council, meaning it now needs to recruit new members to perform the role.
More information is available in VetSurgeon Jobs, here.
"The majority of veterinary medicines used in the UK (and ingredients and components to make them) are either produced in or enter via the EU. The government is working with animal health companies who have been carrying out extensive contingency planning for all EU Exit scenarios, including no deal. These plans cover all aspects of their supply chains, from regulatory compliance and stocking levels to logistics and customs. They also include, as appropriate, increasing stocks of products in the UK, changing supply routes, transferring marketing authorisations and other regulatory processes.
"To reduce any risk to medicines availability in the UK, detailed planning is ongoing to ensure that supply chain measures are appropriate to address the sector’s complex needs and priorities.
"Much work has been done by companies with the objective of ensuring fair and appropriate distribution of this inventory to avoid disruption.
"Supply is expected to cope with a normal ordering pattern with adequate forward planning and communication with suppliers.
"With this planning in place, we are confident that we have made every effort to ensure continuity of supply of veterinary medicines in the UK."
Well that makes a nice change from the incessantly and determinedly gloomy picture painted elsewhere.
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.
Invicta Animal Health has announced the launch of Ocuvance, a nutritional supplement to support ocular health in dogs and cats.
The company says Ocuvance is formulated to provide an antioxidant complex supporting and maintaining the health of eyes. The tablets contain lutein, a xanthophyll pigment found within the eye. They also contain anthocyanosides derived from bilberry extract to support rhodopsin production. The formulation also contains vitamins C and E, zinc and selenium.
Ocuvance is presented in packs of 30 scored tablets; sufficient for a one month supply for the average sized dog.
Rob Watkins, Managing Director of Invicta, said: "We are delighted to make Ocuvance available to veterinary surgeons in the UK. A recent veterinary study1 has shown there can be significant ophthalmic benefits of antioxidant supplementation.
We carefully formulated Ocuvance to provide a range of high quality ingredients to maintain normal visual function whilst still being affordable for owners”.
Ocuvance is now available from all veterinary wholesalers.
Reference
What is 'quality improvement', you ask? Good question. Sure, it's an improvement in, er, quality. But of what?
'Quality improvement' is a term adopted from the human healthcare sector, variously defined as anything which makes: "healthcare safer, effective, patient-centred, timely, efficient and equitable (NHS)", or "the combined and unceasing efforts of everyone—healthcare professionals, patients and their families, researchers, payers, planners and educators—to make the changes that will lead to better patient outcomes (health), better system performance (care) and better professional development (BMJ)."
The RCVS research project, which is being conducted by RAND EUROPE, will assess current perceptions and adoption of quality improvement in the veterinary profession.
Specifically, it'll look at the drivers, barriers and expectations associated with QI, with the ultimate goal of strengthening the support provided to the profession.
Chris Gush, Executive Director of RCVS Knowledge, said: "We are delighted to be launching this research project with RAND Europe.
"We know that many of our colleagues across the profession have embedded quality improvement into their practice to great benefit, while we are also aware that it can be a challenge to do so all of the time.
"This research will provide an unprecedented body of evidence on the experiences and perceptions of QI, which will be critical to how we work to support the sector in this area going forward."
Integral to the research is a survey which all members of the profession are invited to take part in, here: bit.ly/QIvetsurvey.
The survey will be live for six weeks, closing early April. It takes around ten minutes to complete, with a prize of one £150 Amazon voucher on offer. Responses will be anonymised.
You can read more about Quality Improvement on the RCVS Knowledge website, here: https://knowledge.rcvs.org.uk/quality-improvement/
The committee heard five charges against Dr Davies at a resumed hearing of an inquiry which was originally adjourned in January and then July 2018. The decision was made, at both the 2018 hearings, to postpone the final decision on the sanction.
The first two charges against Dr Davies related to convictions for drink driving in March 2014 and October 2015 for which she received driving bans of 17 and 45 months.
The third charge related to her breaching a number of undertakings she had entered into as part of the College’s Health Protocol, including her consuming alcohol on four occasions between May 2015 and January 2016 and missing a pre-arranged appointment with a consultant psychiatrist appointed.
The fourth and fifth charges related to being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016 which was also in breach of her undertakings under the Health Protocol.
At Dr Davies' first Disciplinary Committee hearing in January 2018, she admitted all five charges against her and also accepted that her conduct was disgraceful conduct in a professional respect.
The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At the conclusion of its hearing on 23 January 2018 the Committee decided to postpone its decision regarding sanction for six months on the basis of Dr Davies’ entering into undertakings, including not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement and to undergo blood and hair tests for alcohol consumption every two months.
At the resumed hearing on 30 July 2018, Dr Davies’ Counsel submitted on her behalf that she wished to return to practise and the Committee reviewed evidence that she provided to demonstrate she had complied with her undertakings.
However, the Committee retained concerns about Dr Davies' return to practise and therefore required her to identify a veterinary surgeon who would agree to act as her mentor, noting that the mentor would have to be acceptable to the College as someone suitable to act in that capacity.
The Committee also required the continuation of the requirements for abstinence from alcohol and the programme of blood and hair testing.
A further requirement of the Committee was that Dr Davies should make a disclosure to any new employer of her appearances before the Committee in January 2018 and in July 2018 and of the decisions it made.
The final requirement of the Committee was that the respondent should not accept a ‘sole charge position’ at any time during her employment during this next period of postponement of sanction. The Committee then directed that the hearing be postponed for a further 12 months.
The Disciplinary Committee resumed its inquiry on 7th August 2019, when Dr Davies submitted documentary proof and medical records to demonstrate she had complied with all her undertakings given at the last hearing. The Committee also heard from Dr Davies’ appointed veterinary mentor who provided a statement that concluded that she no longer needed monitoring or supervision.
The Committee then considered what sanction to impose on Dr Davies.
Ian Green, chairing the Committee and speaking on its behalf, said: "The view of the Committee is that the respondent has to date overcome her addiction to alcohol and, given that her competence as a practising veterinary surgeon is not disputed, that she should therefore be permitted to return to her chosen profession. However, in the judgment of this Committee the seriousness of the offences to which the Respondent has pleaded guilty means that a sanction of “No Further Action” cannot be justified."
The Committee therefore decided that the most proportionate sanction was for Dr Davies to be reprimanded as to the conduct she admitted at previous hearings and that she be warned as to her future conduct.
Ian added: "The respondent must understand that she has been given an opportunity to prove that, for the remainder of her time in practice, she can meet the high standards expected of all registered veterinary surgeons from both other practitioners and from members of the public who entrust the care and treatment of their animals to members of this profession."
Under the scheme, 60 students will be given two weeks of supported clinical placements in more than 50 Vets4Pets practices across the UK, helping to prepare them for work in a clinical environment.
Successful applicants will receive £334 per week during their placements and will also have access to a fast-track application to the Vets4Pets Graduate Programme.
Emily Bridges, Vet & Graduate Programme Lead at Vets4Pets said: “While we know that great EMS placements are a key part of a student’s development, we also know that it has become increasingly difficult for students to fund EMS while they are studying.
"By launching the bursary scheme, we’re hoping to provide students with the support they need to get the most out of their placements, without the financial worry."
Jessica Windham, a veterinary graduate from the RVC, London, took part in the pilot. She said: “For me, the bursary helped to pay for my fuel and food while on placement.
"This meant I could go home and rest after eight hours in the practice, instead of going straight to my part-time bar job and working an extra four-hour shift like many students have to do.
"Ultimately because I was less tired, I performed far better as a student and learned a lot more.”
Applications will open in March 2022 for placements beginning in summer, and students can find out more at: www.vets4pets.com/ems
Organisers of The London Vet Show 2009 report that the event was a great sucess, greeted with 'considerable delight' by delegates and exhibitors alike.
The event, which featured clinical and commercial lectures as well as a major exhibition, ran on 6th and 7th November at London's Olympia Conference Centre. 2410 veterinary professionals attended, and most were there for both days.
VetSurgeon.org attended the event, asking commercial exhibitors: "What's New?" Those of you that didn't make it to the show can click here to watch a video of their answers.
Overall feedback from vets about the quality of the CPD programme was overwhelmingly positive. Delegate feedback forms rated the quality of speakers in the programme as 4.39 out of 5, and rated the event as 4.68 out of 5 in terms of value for money.
Rachel Bolus of Riverside Veterinary Practice said: "All the lectures were to a really good standard - a lot of CPD for a very cheap price."
Bridget O'Farrell of Dick Vet Small Animal Practice agreed: "Very cheap for two days of CPD and the quality of the speakers has been very good. I went to five lectures yesterday and planning on six today. It's been a very worthwhile exercise and I would certainly recommend this to my peers".
Event organiser Phil Nelson said: "We have witnessed an amazing two days, surpassing all delegate estimates and it's gone down really well. The 2010 exhibition is already 40% bigger than this year almost 12 months out and looks set to sell out. We are carefully listening to the delegates and exhibitors comments, and have already a number of plans to develop and build the event going forward. But as a starting point we could never have dreamt for the launch event to be so well received."
For 2010 the London Vet Show is moving to the bigger Olympia National Hall having out grown the Conference Centre. It will run on October 22nd and 23rd. It is committed to retaining the same approach to offering affordable and World Class CPD qualifying clinical and commercial content for all the UKs vets. Having very quickly established itself as a major part of the veterinary calendar the organisers expect to announce their 2010 programme in the early part of 2010.
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com
The NOAH Code of Practice Committee, chaired by Mr Guy Tritton, has found Dechra Veterinary Products in breach of three items of the NOAH Code, following a complaint.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
The charity says that one of the biggest issues it faces with guinea pigs is multi-animal households where breeding has become out of control.
Dr Jane Tyson, the RSPCA’s rodent expert, said: "We would always advise owners to have their male guinea pigs neutered before introducing them to a female. We also find that they can sometimes be mis-sexed by the seller or previous owner which leads to accidental breeding so it’s also important to make sure that guinea pigs see a vet regularly who would be able to spot if they have been identified incorrectly.
“Many of the guinea pigs that come into our care have come from a multi-animal home where there have been large numbers of guinea pigs living in often cramped, dirty and unsuitable conditions. This also means that they may have experienced very little handling and are wary and fearful of human hands and need their confidence building up in RSPCA care.
“This is why, this Guinea Pig Appreciation Day, we wanted to encourage people to neuter their guinea pigs and help tackle the problem of overbreeding.”
The Cheshire-based specialist referral centre provides advanced surgical procedures and specialist veterinary support to practices in north west England and north and mid-Wales.
Its specialist disciplines include orthopaedics, soft tissue surgery, a specialist diabetes clinic, spinal surgery, anaesthesia and intensive care, cardiology, diagnostic imaging, pain management, neurology (medical and surgical), oncology and internal medicine.
Liz Cousins, Northwest's Hospital Manager said: "Following our recent brand transition from Northwest Surgeons to Northwest Veterinary Specialists we are delighted to receive this accreditation.
"The scheme examines every part of what we do, from customer experience, equipment and facilities right through to clinical governance. In a hospital with more than 85 colleagues, that’s a lot of work to do to meet the high standards.
"Our new brand name reflects the range of specialist services we offer and this accreditation gives confidence to fellow veterinary surgeons and pet owners that we really do offer the very best specialist care for pets.
"We continually strive for excellence across the business, and this is another way of demonstrating just how good the specialists are at Northwest Veterinary Specialists."
Picture shows: Matt Gurney, European Veterinary Specialist in Anaesthesia and Analgesia (centre) with Kathryn Humphreys, Head of Nursing, (right), Jenny Pearson, support Services Manager, (left) with the RCVS Hospital Accreditation.
Norbrook has verified that the pH of certain batches has increased over time and is out of specification.
This issue impacts the following batches:
A spokesperson said: "There has been no increased risk to animal safety identified but we take quality extremely seriously so we initiated a voluntary recall. We have informed all of the competent authorities and we are working with our distributor to advise immediate quarantine of any remaining inventory."
If you have any questions concerning the recall, contact Ms. Anita Vanderlaan Tel: +44 (0)28 3026 4435, Email: anita.vanderlaan@norbrook.co.uk
The British Veterinary Association has welcomed the tightening up of sales of veterinary medicines on the internet but has expressed disappointment that the advertising of antimicrobials to farmers will continue.
The Veterinary Medicines Directorate has today published its response to the public consultation on the Veterinary Medicines Regulations, which are updated every year.
The new Regulations, which come into force in April 2011, introduce new controls on internet pharmacies meaning that only approved websites will be legally allowed to dispense and supply veterinary medicines. The controls will come into force in April 2012 and the BVA supports the use of a logo on approved websites to help consumers buy medicines from reputable sources.
The BVA has previously expressed concern that pet owners could inadvertently buy counterfeit veterinary medicines online and urges veterinary clients to seek advice from their vet and only buy from UK-based companies.
Harvey Locke, President of the BVA, said: "Without proper regulation online pharmacies could be sourcing drugs from overseas and selling counterfeit medicines that look genuine to unsuspecting pet owners. These medicines are placebos at best and dangerous at worst.
"We therefore welcome the VMD's decision to clampdown on irresponsible online retailers and provide a clear logo for approved websites that will give pet owners confidence.
"We have also asked the VMD to put a stop to the increasing problem of prescription fraud and we hope the tighter regulation announced today will be a step towards achieving that aim.
"However, we would urge all pet owners to continue talking to their vet about sourcing medicines from the internet to make sure the right drugs are bought and administered correctly."
In light of increasing concerns about the growth of antimicrobial resistance the VMD's consultation canvassed views on restricting the advertising of antimicrobials to farmers. The BVA says it supported a ban on advertising as a sensible approach to the responsible use of antimicrobials, and is disappointed that the VMD has decided not to go ahead with it. Mr Locke said: "New antimicrobials are heavily advertised by pharmaceutical companies to vets and farmers so it is vital that the message of responsible use is not lost.
"Antimicrobial resistance is a serious issue for both animal and human health and we are disappointed that the VMD is not restricting the advertising of these products to farmers. The pharmaceutical companies must now undertake to advertise responsibly.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets and farmers should work together to ensure antimicrobials are used prudently and responsibly."
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
Armed with the new microscope, New Forest Equine Vets (NFEV) has started offering a mobile equine veterinary service, including expert worming advice.
The microscope captures images with a resolution of 1 micron, with a live magnification of x200 and x400 or more, which means that the practice can carry out an accurate egg count in the yard, rather than sending faecal samples off to the lab.
This, they say, allows for a more a more accurate result, because posting faeces can lead to the sample desiccating and the eggs hatching, leading to false negative results. It also allows the veterinary surgeon to give immediate advice and treatment.
Dr. Beth Robinson BVSc Cert AVP(EP) MRCVS, co-owner of NFEV, says "One of the main aims of performing worm egg counts is to identify horses shedding low numbers of eggs so that we can maintain a low number of parasites on the pasture that have not been exposed to wormers and therefore have not been placed under selection pressure for resistance. In horses shedding high numbers of eggs, worm egg count reduction tests are a useful way of assessing whether treatment has been effective."
Andrew Monk, co-founder of ioLight, said: "The product is incredibly simple to use. By using a tablet both the owner and vet can view the image and discuss treatment. We hope that more horse owners in the New Forest will use the services from NFEV to protect their animals, and that it will encourage other equine practices to purchase a microscope so they can also offer a similar high quality service. We have made a video with NFEV to demonstrate their service and encourage other equine vets to use the ioLight microscope in their own mobile clinics."
Beth added: "We are delighted to be working with ioLight and horse owners to keep their animals healthy and improve equine welfare."